252P - Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Jose Luis Perez Gracia
Citation Annals of Oncology (2014) 25 (suppl_4): iv58-iv84. 10.1093/annonc/mdu326
Authors J.L. Perez Gracia1, M.F. Sanmamed2, O.E. Carranza Rua1, C. Alfaro3, C. Oñate4, S. Martin-Algarra1, G. Perez5, S. F. Landázuri6, A. Gonzalez6, S. Gross7, I. Rodriguez Lopez3, C. Muñoz-Calleja8, M.E. RodrÍguez-Ruiz3, B. Sangro9, J.M. Lopez-Picazo10, M. Rizzo11, G. Mazzolini11, I. Melero1
  • 1Department Of Oncology, Clínica Universidad de Navarra, 31008 - Pamplona/ES
  • 2Clinical Oncology, Clinica Universitaria de Navarra, 31008 - Pamplona/ES
  • 3Immunotherapy, Centro de Investigacion Medica Aplicada, pamplona/ES
  • 4Inmunotherapia, Centro de Investigación Médica Aplicada, Pamplona/ES
  • 5Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona/ES
  • 6Department Of Biochemistry, Clínica Universidad de Navarra, 31008 - Pamplona/ES
  • 7Department Of Dermatology, University Hospital Erlangen, Erlangen/DE
  • 8Department Of Immunology, Hospital Universitario de la Princesa, Madrid/ES
  • 9Hepathology, Clinica Universitaria de Navarra, 31008 - Pamplona/ES
  • 10Oncology Department, Clinica Universidad de Navarra, 31008 - Pamplona/ES
  • 11Internal Medicine, Universidad Austral, Buenos Aires/AR



IL-8 is produced by multiple tumors and its functions include regulation of tumor angiogenesis and immune response. We evaluated the correlation of IL-8 with tumor burden and its potential role as a cancer biomarker by studying sequential levels of serum IL-8 in preclinical tumor models and in patients with multiple tumor types, at baseline and following anticancer treatment.


IL-8 levels were monitored sequentially by sandwich ELISAs in three different models: a) cultured tumor cells supernatant; b) serum of tumor-xenografted mice and; c) serum and urine samples from 119 cancer patients, at baseline and following diverse anticancer treatments. We correlated IL-8 levels with tumor burden, treatment induced response and cancer prognosis.


IL-8 levels showed a strong correlation with tumor burden in all the models explored: a) in tumor cultures, IL-8 levels correlated accurately with the number of cancer cells; b) in tumor-xenografted mice, IL-8 serum levels correlated with tumor burden and rapidly dropped following surgical excision; and c) in patients with melanoma, renal-cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma, serum IL-8 levels correlated with tumor burden and stage, survival and objective responses to therapy, including BRAF inhibitors and immunomodulatory monoclonal-antibodies. IL-8 concentrations in urine were mainly elevated in tumors with direct contact with the urinary tract.


IL-8 levels correlate with tumor burden in preclinical models and in cancer patients and are a potentially useful biomarker to monitor response to cancer treatment. This might be particularly relevant to assess the therapeutic effects of drugs that may induce “pseudo-progressions”, such as immunomodulatory monoclonal antibodies.


All authors have declared no conflicts of interest.